{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T23:01:01Z","timestamp":1782860461570,"version":"3.54.5"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Novaliq GmbH, Germany"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.ejpb.2019.06.008","type":"journal-article","created":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T21:11:59Z","timestamp":1560201119000},"page":"83-91","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Topical semifluorinated alkane-based azithromycin suspension for the management of ocular infections"],"prefix":"10.1016","volume":"142","author":[{"given":"Priyanka","family":"Agarwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer P.","family":"Craig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Kr\u00f6sser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Eickhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Swift","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilva D.","family":"Rupenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2019.06.008_b0005","doi-asserted-by":"crossref","unstructured":"A. Ludwig, H. Reimann, Eye, in: Y. Bouwman-Boer, V.I. Fenton-May, P. Le Brun (Eds.), Practical Pharmaceutics: An International Guideline for the Preparation, Care and Use of Medicinal Products, Springer International Publishing, Berlin, Germany, 2015, pp. 163\u2013188.","DOI":"10.1007\/978-3-319-15814-3_10"},{"key":"10.1016\/j.ejpb.2019.06.008_b0010","article-title":"A pilot study: the efficacy of virgin coconut oil as ocular rewetting agent on rabbit eyes","volume":"135987","author":"Mutalib","year":"2015","journal-title":"Evidence-based Complem. Alternat. Med.: eCAM 2015"},{"issue":"11","key":"10.1016\/j.ejpb.2019.06.008_b0015","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1016\/S0161-6420(02)01262-9","article-title":"Low-concentration homogenized castor oil eye drops for noninflamed obstructive meibomian gland dysfunction","volume":"109","author":"Goto","year":"2002","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.ejpb.2019.06.008_b0020","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1136\/bjo.74.6.350","article-title":"Ocular penetration of cyclosporin A. III: the human eye","volume":"74","author":"BenEzra","year":"1990","journal-title":"Br. J. Ophthalmol."},{"issue":"3","key":"10.1016\/j.ejpb.2019.06.008_b0025","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/0002-9394(86)90819-6","article-title":"Cyclosporine eyedrops for the treatment of severe vernal keratoconjunctivitis","volume":"101","author":"BenEzra","year":"1986","journal-title":"Am. J. Ophthalmol."},{"issue":"4","key":"10.1016\/j.ejpb.2019.06.008_b0030","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.nano.2008.06.003","article-title":"Ocular nanoparticle toxicity and transfection of the retina and retinal pigment epithelium","volume":"4","author":"Prow","year":"2008","journal-title":"Nanomedicine"},{"issue":"1","key":"10.1016\/j.ejpb.2019.06.008_b0035","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/bmb\/ldv002","article-title":"Critical appraisal of alternative irritation models: three decades of testing ophthalmic pharmaceuticals","volume":"113","author":"Abdelkader","year":"2015","journal-title":"Br. Med. Bull."},{"issue":"4","key":"10.1016\/j.ejpb.2019.06.008_b0040","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.preteyeres.2010.03.001","article-title":"Preservatives in eyedrops: the good, the bad and the ugly","volume":"29","author":"Baudouin","year":"2010","journal-title":"Prog. Retin. Eye Res."},{"issue":"2","key":"10.1016\/j.ejpb.2019.06.008_b0045","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s002849900290","article-title":"Azithromycin and clarithromycin inhibition of 50S ribosomal subunit formation in Staphylococcus aureus cells","volume":"36","author":"Champney","year":"1998","journal-title":"Curr. Microbiol."},{"issue":"1","key":"10.1016\/j.ejpb.2019.06.008_b0050","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1097-2765(02)00570-1","article-title":"The structures of four macrolide antibiotics bound to the large ribosomal subunit","volume":"10","author":"Hansen","year":"2002","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejpb.2019.06.008_b0055","first-page":"1797","article-title":"Emerging treatment options for meibomian gland dysfunction","volume":"7","author":"Qiao","year":"2013","journal-title":"Clin. Ophthalmol."},{"issue":"4","key":"10.1016\/j.ejpb.2019.06.008_b0060","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1203\/PDR.0b013e318142582d","article-title":"Azithromycin suppresses activation of nuclear factor-kappa B and synthesis of pro-inflammatory cytokines in tracheal aspirate cells from premature infants","volume":"62","author":"Aghai","year":"2007","journal-title":"Pediatr. Res."},{"issue":"1","key":"10.1016\/j.ejpb.2019.06.008_b0065","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/112067210801800103","article-title":"Tear concentrations of azithromycin following topical administration of a single dose of azithromycin 0.5%, 1.0%, and 1.5% eyedrops (T1225) in healthy volunteers","volume":"18","author":"Chiambaretta","year":"2008","journal-title":"Eur. J. Ophthalmol."},{"issue":"1","key":"10.1016\/j.ejpb.2019.06.008_b0070","first-page":"3","article-title":"Clinical development of 1% azithromycin in DuraSite(\u00ae), a topical azalide anti-infective for ocular surface therapy","volume":"1","author":"Friedlaender","year":"2007","journal-title":"Clin. Ophthalmol."},{"issue":"7","key":"10.1016\/j.ejpb.2019.06.008_b0075","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.3109\/03639045.2014.931967","article-title":"Amorphous azithromycin with improved aqueous solubility and intestinal membrane permeability","volume":"41","author":"Aucamp","year":"2015","journal-title":"Drug Dev. Ind. Pharm."},{"issue":"3","key":"10.1016\/j.ejpb.2019.06.008_b0080","doi-asserted-by":"crossref","first-page":"215","DOI":"10.4103\/0301-4738.40360","article-title":"Medical management approach to infectious keratitis","volume":"56","author":"Gokhale","year":"2008","journal-title":"Indian J. Ophthalmol."},{"key":"10.1016\/j.ejpb.2019.06.008_b0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4137\/OED.S7791","article-title":"Review of azithromycin ophthalmic 1% solution (AzaSite(\u00ae)) for the treatment of ocular infections","volume":"4","author":"Opitz","year":"2012","journal-title":"Ophthalmol. Eye Dis."},{"issue":"4","key":"10.1016\/j.ejpb.2019.06.008_b0090","first-page":"519","article-title":"An assessment of the tolerability of moxifloxacin 0.5% compared to azithromycin 1.0% in DuraSite(\u00ae)","volume":"1","author":"Granet","year":"2007","journal-title":"Clin. Ophthalmol."},{"issue":"9","key":"10.1016\/j.ejpb.2019.06.008_b0095","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1007\/s12325-008-0096-9","article-title":"Efficacy of topical azithromycin ophthalmic solution 1% in the treatment of posterior blepharitis","volume":"25","author":"Luchs","year":"2008","journal-title":"Adv. Ther."},{"issue":"4","key":"10.1016\/j.ejpb.2019.06.008_b0100","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ajo.2010.05.006","article-title":"An anterior chamber toxicity study evaluating besivance, AzaSite, and ciprofloxacin","volume":"150","author":"Ness","year":"2010","journal-title":"Am. J. Ophthalmol."},{"issue":"10","key":"10.1016\/j.ejpb.2019.06.008_b0105","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1097\/ICO.0b013e31829e1e8c","article-title":"Delayed epithelial closure after PRK associated with topical besifloxacin use","volume":"32","author":"Talamo","year":"2013","journal-title":"Cornea"},{"issue":"3","key":"10.1016\/j.ejpb.2019.06.008_b0110","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2165\/11208580-000000000-00000","article-title":"Azithromycin 1.5% ophthalmic solution","volume":"72","author":"Garnock-Jones","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.ejpb.2019.06.008_b0115","unstructured":"Spectrum Thea Pharmaceuticals Ltd., Azyter\u00ae (azithromycin dihydrate 1.5% ophthalmic solution): summary of product characteristics [online], 2013. http:\/\/www.medicines.org.uk\/EMC\/medicine\/24743\/SPC\/Azyter\/. (accessed 16 Novemener, 2017 2017)."},{"issue":"1","key":"10.1016\/j.ejpb.2019.06.008_b0120","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1869-5760-3-38","article-title":"Efficacy of azithromycin 1.5% eye drops in childhood ocular rosacea with phlyctenular blepharokeratoconjunctivitis","volume":"3","author":"Doan","year":"2013","journal-title":"J. Ophthalmic Inflamm. Infect."},{"key":"10.1016\/j.ejpb.2019.06.008_b0125","first-page":"2195","article-title":"Ocular safety of cationic emulsion of cyclosporine in an in vitro corneal wound-healing model and an acute in vivo rabbit model","volume":"18","author":"Liang","year":"2012","journal-title":"Mol. Vis."},{"issue":"8","key":"10.1016\/j.ejpb.2019.06.008_b0130","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1248\/bpb1978.8.633","article-title":"Improvement of bioavailability of poorly absorbed drugs. III. Oral acute toxicity and local irritation of medium chain glyceride","volume":"8","author":"Sekine","year":"1985","journal-title":"J. Pharmacobiodyn."},{"issue":"1","key":"10.1016\/j.ejpb.2019.06.008_b0135","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijpharm.2018.01.019","article-title":"Semifluorinated alkane based systems for enhanced corneal penetration of poorly soluble drugs","volume":"538","author":"Agarwal","year":"2018","journal-title":"Int. J. Pharm."},{"issue":"8","key":"10.1016\/j.ejpb.2019.06.008_b0140","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1089\/jop.2015.0048","article-title":"Semifluorinated alkane eye drops for treatment of dry eye disease\u2013a prospective, multicenter noninterventional study","volume":"31","author":"Steven","year":"2015","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2019.06.008_b0145","unstructured":"C.G. Wilson, Liquid pharmaceutical composition for the treatment of a posterior eye disease, in: United States Patent and Trademarks Office (Ed.) Washington D.C., Novaliq GmbH, 2012."},{"issue":"9","key":"10.1016\/j.ejpb.2019.06.008_b0150","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1089\/jop.2017.0042","article-title":"Semifluorinated alkane eye drops for treatment of dry eye disease due to meibomian gland disease","volume":"33","author":"Steven","year":"2017","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2019.06.008_b0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00417-016-3572-y","article-title":"A semifluorinated alkane (F4H5) as novel carrier for cyclosporine A: a promising therapeutic and prophylactic option for topical treatment of dry eye","volume":"255","author":"Gehlsen","year":"2017","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"issue":"2","key":"10.1016\/j.ejpb.2019.06.008_b0160","first-page":"218","article-title":"Cellular pharmacodynamics and pharmacokinetics of antibiotics: Current views and perspectives","volume":"9","author":"Van Bambeke","year":"2006","journal-title":"Curr. Opin. Drug Discov. Devel."},{"issue":"7","key":"10.1016\/j.ejpb.2019.06.008_b0165","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1128\/AAC.47.7.2283-2292.2003","article-title":"Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular staphylococcus aureus in mouse J774 macrophages","volume":"47","author":"Seral","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejpb.2019.06.008_b0170","unstructured":"CLSI, Methods for Dilution Antimicrobial Susceptibility, Tests f or Bacteria That Grow Aerobically; Approved St andard\u2014Ninth Edition, CLSI document M07-A9, Clinical and Laboratory Standards Institute, Wayne, PA, 2012."},{"issue":"10","key":"10.1016\/j.ejpb.2019.06.008_b0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140446","article-title":"Using an adenosine triphosphate bioluminescent assay to determine effective antibiotic combinations against carbapenem-resistant gram negative bacteria within 24 hours","volume":"10","author":"Cai","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.ejpb.2019.06.008_b0180","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00417-016-3546-0","article-title":"Ex vivo rabbit and human corneas as models for bacterial and fungal keratitis","volume":"255","author":"Pinnock","year":"2017","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"issue":"6","key":"10.1016\/j.ejpb.2019.06.008_b0185","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1007\/s13346-015-0275-6","article-title":"In vitro and ex vivo corneal penetration and absorption models","volume":"6","author":"Agarwal","year":"2016","journal-title":"Drug Deliv. Transl. Res."},{"issue":"9","key":"10.1016\/j.ejpb.2019.06.008_b0190","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1248\/bpb.b17-00288","article-title":"Limited azithromycin localization to rabbit meibomian glands revealed by LC-MS-based bioanalysis and DESI imaging","volume":"40","author":"Asano","year":"2017","journal-title":"Biol. Pharm. Bull."},{"issue":"3","key":"10.1016\/j.ejpb.2019.06.008_b0195","first-page":"627","article-title":"Characterization of paracellular and aqueous penetration routes in cornea, conjunctiva, and sclera","volume":"38","author":"H\u00e4m\u00e4l\u00e4inen","year":"1997","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"6","key":"10.1016\/j.ejpb.2019.06.008_b0200","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.ajo.2008.01.025","article-title":"Ocular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolates","volume":"145","author":"Asbell","year":"2008","journal-title":"Am. J. Ophthalmol."},{"issue":"3","key":"10.1016\/j.ejpb.2019.06.008_b0205","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0924-8579(96)00320-2","article-title":"Comparative antimicrobial activity and post-antibiotic effect of azithromycin, clarithromycin and roxithromycin against some respiratory pathogens","volume":"7","author":"Ferrara","year":"1996","journal-title":"Int. J Antimicrob. Agents"},{"issue":"12","key":"10.1016\/j.ejpb.2019.06.008_b0210","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1345\/aph.19074","article-title":"A time-kill evaluation of clarithromycin and azithromycin against two extracellular pathogens and the development of resistance","volume":"33","author":"Burgess","year":"1999","journal-title":"Ann. Pharmacother."},{"issue":"3","key":"10.1016\/j.ejpb.2019.06.008_b0215","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1086\/596051","article-title":"Treatment with protein synthesis inhibitors improves outcomes from secondary bacterial pneumonia following influenza","volume":"199","author":"Karlstr\u00f6m","year":"2009","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ejpb.2019.06.008_b0220","unstructured":"M. Abrams, D. Goldberg, J. Luchs, K. Nichols, S. Rauchman, K. Sall, J. Sheppard, J. Tauber, Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease (Maui), 2014. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02218489?term=KPI-121&rank=3. 2014)."},{"issue":"1","key":"10.1016\/j.ejpb.2019.06.008_b0225","first-page":"43","article-title":"Antibacterial study of the medium chain fatty acids and their 1-monoglycerides: individual effects and synergistic relationships","volume":"58","author":"Batovska","year":"2009","journal-title":"Pol. J. Microbiol."},{"issue":"1","key":"10.1016\/j.ejpb.2019.06.008_b0230","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.vetmic.2012.05.017","article-title":"The intramammary efficacy of first generation cephalosporins against Staphylococcus aureus mastitis in mice","volume":"160","author":"Demon","year":"2012","journal-title":"Vet. Microbiol."},{"issue":"10","key":"10.1016\/j.ejpb.2019.06.008_b0235","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.3168\/jds.S0022-0302(05)73033-2","article-title":"Antibacterial effect of caprylic acid and monocaprylin on major bacterial mastitis pathogens","volume":"88","author":"Nair","year":"2005","journal-title":"J. Dairy Sci."},{"issue":"6","key":"10.1016\/j.ejpb.2019.06.008_b0240","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1089\/jop.2010.0097","article-title":"AzaSite(\u00ae) inhibits staphylococcus aureus and coagulase-negative staphylococcus biofilm formation in vitro","volume":"26","author":"Wu","year":"2010","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2019.06.008_b0245","unstructured":"A. Asero, A.R. Blanco, M.G. Mazzone, V. Moschetti, Process for the preparation of aqueous formulations for ophthalmic use in: US Patents and Trademarks Office (Ed.) Washington D.C., S.I.F.I. Societa Industria Farmaceutica Italiana S.P.A., 2001."},{"issue":"6","key":"10.1016\/j.ejpb.2019.06.008_b0250","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1128\/iai.62.6.2478-2482.1994","article-title":"Corneal virulence of Staphylococcus aureus: roles of alpha-toxin and protein A in pathogenesis","volume":"62","author":"Callegan","year":"1994","journal-title":"Infect. Immun."},{"issue":"2","key":"10.1016\/j.ejpb.2019.06.008_b0255","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/ceo.12810","article-title":"Ocular surface microbiome in meibomian gland dysfunction","volume":"45","author":"Watters","year":"2017","journal-title":"Clin. Experiment. Ophthalmol."},{"issue":"5","key":"10.1016\/j.ejpb.2019.06.008_b0260","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1167\/iovs.03-1067","article-title":"Conjunctival proinflammatory and proapoptic effects of latanoprost and preserved and unpreserved timolol: An ex vivo and in vivo study","volume":"45","author":"Pisella","year":"2004","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"3","key":"10.1016\/j.ejpb.2019.06.008_b0265","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/00003226-199211030-00006","article-title":"Confocal microscopic studies of living rabbit cornea treated with benzalkonium chloride","volume":"11","author":"Ichijima","year":"1992","journal-title":"Cornea"},{"issue":"9","key":"10.1016\/j.ejpb.2019.06.008_b0270","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.2042-7158.1995.tb06726.x","article-title":"Ophthalmic preservatives as absorption promoters for ocular drug delivery","volume":"47","author":"Sasaki","year":"1995","journal-title":"J. Pharm. Pharmacol."},{"issue":"5","key":"10.1016\/j.ejpb.2019.06.008_b0275","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1089\/jop.2009.0026","article-title":"Ocular surface distribution and pharmacokinetics of a novel ophthalmic 1% azithromycin formulation","volume":"25","author":"Akpek","year":"2009","journal-title":"J. Ocul. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.ejpb.2019.06.008_b0280","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/02713680701860499","article-title":"Ocular pharmacokinetic study following single and multiple azithromycin administrations in pigmented rabbits","volume":"33","author":"Amar","year":"2008","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.ejpb.2019.06.008_b0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtos.2019.02.010","article-title":"Preclinical studies evaluating the effect of semifluorinated alkanes on ocular surface and tear fluid dynamics","author":"Agarwal","year":"2019","journal-title":"Ocul. Surf."},{"issue":"3","key":"10.1016\/j.ejpb.2019.06.008_b0290","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1128\/AAC.50.3.841-851.2006","article-title":"Pharmacodynamic Evaluation of the Intracellular Activities of Antibiotics against Staphylococcus aureus in a Model of THP-1 Macrophages","volume":"50","author":"Barcia-Macay","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.ejpb.2019.06.008_b0295","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1128\/AAC.01605-07","article-title":"Intracellular activity of antibiotics against staphylococcus aureus in a mouse peritonitis model","volume":"53","author":"Sandberg","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejpb.2019.06.008_b0300","doi-asserted-by":"crossref","first-page":"(S259)","DOI":"10.1111\/j.1755-3768.2017.0S029","article-title":"Exploratory ocular surface distribution studies of Azithromycin formulations based on semifluorinated alkanes","volume":"95","author":"Fischer","year":"2017","journal-title":"Acta Ophthalmol."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641119304254?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641119304254?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:34:54Z","timestamp":1760546094000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641119304254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":60,"alternative-id":["S0939641119304254"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2019.06.008","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Topical semifluorinated alkane-based azithromycin suspension for the management of ocular infections","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2019.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}